Retatrutide for Obesity

(TRIUMPH-8 Trial)

Not yet recruiting at 31 trial locations

Overseen By Physicians interested in becoming principal investigators please contact

Age: 18+

Sex: Any

Trial Phase: Phase 3

Sponsor: Eli Lilly and Company

Pivotal Trial (Near Approval) This treatment is in the last trial phase before FDA approval

Prior Safety Data This treatment has passed at least one previous human trial

Compensation: Varies

Number of Visits: Unknown

What You Need to Know Before You Apply

What is the purpose of this trial?

The purpose of this study is to evaluate the efficacy and safety of retatrutide compared with placebo for body weight reduction.

Participation in the study will last about 65 weeks and may include about 18 visits.

Who Is on the Research Team?

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)

Principal Investigator

Eli Lilly and Company

Are You a Good Fit for This Trial?

This trial is for individuals who are overweight or have obesity. Participants will be involved in the study for about 65 weeks and should expect around 18 visits.

Inclusion Criteria

My BMI is over 30, or it's over 27 with a condition like high blood pressure.

Have at least one unsuccessful attempt to lose weight by dieting

Exclusion Criteria

I have a history of MTC or MEN-2 in my family or myself.

I haven't had a heart attack, stroke, or severe heart issues in the last 3 months.

I have not taken any weight loss drugs in the last 90 days.

What Are the Treatments Tested in This Trial?

Interventions

• Retatrutide

Trial Overview The study aims to test the effectiveness and safety of a new medication called Retatrutide, comparing it with a placebo (a substance with no active drug) to see if it helps reduce body weight.

How Is the Trial Designed?

Group I: Retatrutide Dose 2 Experimental Treatment 1 Intervention

Participants will receive retatrutide SC

Group II: Retatrutide Dose 1 Experimental Treatment 1 Intervention

Participants will receive retatrutide subcutaneously (SC)

Group III: Placebo Placebo Group 1 Intervention

Participants will receive placebo SC

Who Is Running the Clinical Trial?

Eli Lilly and Company

Lead Sponsor

Trials

2,708

Recruited

3,720,000+

Dr. Daniel Skovronsky

Eli Lilly and Company

Chief Medical Officer since 2018

MD from Harvard Medical School

David A. Ricks

Eli Lilly and Company

Chief Executive Officer since 2017

BSc from Purdue University, MBA from Indiana University